Yahoo! Finance Search - Finance Home - Yahoo! - Help

Thursday, September 29 2016 5:35pm ET - U.S. Markets Closed.
Industry Center - Drug Delivery
Industry Center > Drug Delivery > News
More On This Industry
· Summary
News
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Biotechnology
· Diagnostic Substances
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
 
Drug Delivery News
Latest News
Tuesday, Sep 27, 2016
·Drug Price Bubble A Result Of Decade-Long Economic Policy Issues
- Tue 2:01 pm ET
Monday, Sep 26, 2016
·Changes at the Top for Endo Could Benefit Its Smaller Partners
at TheStreet.com - Mon Sep 26
Sunday, Sep 25, 2016
·Wealth Preservation: "All I Know Is That I Know Nothing"
at Investopedia - Sun Sep 25
Friday, Sep 23, 2016
·Valeant Needs Time If It Is to Recover and Rise
at TheStreet.com - Fri Sep 23
Thursday, Sep 22, 2016
·Intellipharmaceutics Responds to Recent Trading Activity
GlobeNewswire - Thu Sep 22
·[$$] SEC's pursuit of Leon Cooperman rattles hedge fund industry
at FT.com - Thu Sep 22
·Aradigm Announces Last Patient Dosing Visit in ORBIT-3 and ORBIT-4 Phase 3 Studies of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis Patients
Business Wire - Thu Sep 22
·[$$] Mylan chief comes under fire over cost of EpiPen
at FT.com - Wed Sep 21
Wednesday, Sep 21, 2016
·Valeant (VRX) Stock Higher on Potential $1 Billion iNova Sale
at TheStreet.com - Wed Sep 21
·Aradigm to Host Analyst Meeting and Webcast on September 26 in New York City
Business Wire - Wed Sep 21
Tuesday, Sep 20, 2016
·Valeant Pharmaceuticals: Remember Them?
at Barrons.com - Tue Sep 20
·Valeant (VRX) Stock Receives 'Hold' Rating at Deutsche Bank
at TheStreet.com - Tue Sep 20
·Aradigm to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27
Business Wire - Tue Sep 20
Monday, Sep 19, 2016
·Flamel Technologies to Present at Ladenburg Thalmann 2016 Healthcare Conference
Marketwire - Mon Sep 19
·Alkermes Announces Webcast of Analyst and Investor Event on September 26, 2016
Business Wire - Mon Sep 19
·Valeant has started taking a huge risk
Business Insider - Mon Sep 19
·Delcath Sponsors Ocular Melanoma Foundation Patient Retreat
PR Newswire - Mon Sep 19
·Valeant Keeps Raising Drug Prices, Stock Still Carries Too Much Risk: Wells Fargo
- Mon Sep 19
·Flamel Technologies to Host Investor & Analyst Meeting
Marketwire - Mon Sep 19
·From a wrist slap to jail time: how the SEC deals with dodgy accounting
at MarketWatch - Mon Sep 19
More Latest News...
  

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Drug Delivery Headlines
More Finance RSS Feeds


Copyright © 2016 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2016 Morningstar, Inc. All Rights Reserved. Company information © 2016 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2016, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?